Replies to post #191776 on Biotech Values

[DewDiligence]

ACT expects Viberzi to have similar peak sales as Linzess (which treats IBS-C rather than IBS-D), according to today’s Bernstein webcast.

[DewDiligence]

AGN, IRWD ink co-promotion agreement for Viberzi:

http://finance.yahoo.com/news/ironwood-allergan-enter-agreement-co-132500942.html

Under the terms of the agreement, Ironwood’s clinical sales specialists will detail VIBERZI to the approximately 25,000 health care practitioners to whom they currently detail LINZESS and Cologuard. LINZESS will remain the first-position product for the Ironwood sales team. Ironwood’s promotional efforts will be compensated based on the volume of calls delivered by Ironwood’s sales force, as well as agreed upon performance metrics. Allergan will be responsible for all other costs relating to the commercialization of VIBERZI. The co-promotion will begin as soon as VIBERZI is commercially available.

IRWD is also co-promoting EXAS’ Cogoguard test.

[DewDiligence]

DEA proposes Schedule-IV for Viberzi:

http://t.co/clE4s5iUDx

[DewDiligence]

Viberzi will have DEA Schedule IV, according to AGN's webcast today.